Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Contrast-enhanced Computed Tomography Features of Microvascular Invasion Predict Response to Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor in Intermediate-stage Hepatocellular Carcinoma

NCT07449065 is registered in ClinicalTrials.gov with First Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT07449065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07449065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Contrast-enhanced Computed Tomography Features of Microvascular Invasion Predict Response to Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor in Intermediate-stage Hepatocellular Carcinoma
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University
Phase
Observational
Overall status
Completed
Start date
June 1, 2018
Completion date
October 31, 2025
Enrollment
324 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc), microvascular invasion (mvi), transarterial chemoembolization, tyrosine kinase inhibitors